TENAX THERAPEUTICS, INC. financial data

Symbol
TENX on Nasdaq
Location
Chapel Hill, NC
Fiscal year end
31 December
Latest financial report
10-K - Q4 2025 - 10 Mar 2026

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 2231% % 11%
Debt-to-equity 4.7% % -10%
Return On Equity -52% % -55%
Return On Assets -50% % -56%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 17,197,613 shares 333%
Common Stock, Shares, Outstanding 9,314,130 shares 172%
Entity Public Float $23,840,749 USD 305%
Common Stock, Value, Issued $1,000 USD
Weighted Average Number of Shares Outstanding, Basic 39,217,244 shares 157%
Weighted Average Number of Shares Outstanding, Diluted 39,217,244 shares 157%

Income Statement

Label TTM Value / Value Unit Change %
Revenue from Contract with Customer, Excluding Assessed Tax $0 USD
Research and Development Expense $32,672,000 USD 157%
General and Administrative Expense $23,713,000 USD 249%
Operating Income (Loss) $56,385,000 USD -189%
Net Income (Loss) Attributable to Parent $52,599,000 USD -199%
Earnings Per Share, Basic -1.34 USD/shares -17%
Earnings Per Share, Diluted -1.34 USD/shares -17%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value $97,600,000 USD 2.8%
Other Assets, Current $1,019,000 USD 1492%
Assets, Current $104,227,000 USD 7.8%
Other Assets, Noncurrent $0 USD -100%
Assets $104,227,000 USD 7.8%
Accounts Payable, Current $6,041,000 USD 91%
Employee-related Liabilities, Current $898,000 USD -33%
Accrued Liabilities, Current $1,115,000 USD -27%
Liabilities, Current $7,156,000 USD 52%
Liabilities $7,156,000 USD 52%
Retained Earnings (Accumulated Deficit) $367,454,000 USD -17%
Stockholders' Equity Attributable to Parent $97,071,000 USD 5.5%
Liabilities and Equity $104,227,000 USD 7.8%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities $6,967,000 USD -35%
Net Cash Provided by (Used in) Financing Activities $23,563,000 USD 197%
Net Cash Provided by (Used in) Investing Activities $0 USD
Common Stock, Shares Authorized 400,000,000 shares 0%
Common Stock, Shares, Issued 9,314,130 shares 172%
Common Stock, Par or Stated Value Per Share 0.0001 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents $97,565,000 USD 2.9%
Interest Paid, Excluding Capitalized Interest, Operating Activities $0 USD -100%
Deferred Tax Assets, Valuation Allowance $50,383,000 USD 21%
Depreciation $6,570 USD 53%
Deferred Tax Assets, Operating Loss Carryforwards $45,621,000 USD 21%
Additional Paid in Capital $464,524,000 USD 14%
Deferred Tax Assets, Net of Valuation Allowance $0 USD
Share-based Payment Arrangement, Expense $18,800,000 USD 1780%
Interest Expense $23,000 USD -4.2%